Dual-Function Microfluidic Chip for Identification and Drug Response Testing of Lung Cancer Organoids

Organoids, as a novel in vitro drug screening platform, have received widespread attention due to their relevance to clinical research as they are derived from patient samples. Lung cancer organoids are categorized into two subtypes: EGFR mutation type and EGFR wild type. EGFR mutation lung cancer organoids exhibit better therapeutic effects with tyrosine kinase inhibitors (TKIs), whereas EGFR wild type lung cancer organoids have better responses to chemotherapy drugs. However, the current lack of a microfluidic chip capable of identifying EGFR mutations in lung cancer organoids and testing their drug response poses a challenge. To address this, we have developed a dual-functional chip that streamlines EGFR mutation identification and drug testing in lung cancer organoids. This method not only reduces time and cost but also enhances drug screening efficiency.